MedTrace Logo

A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

NCT02608359 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-02-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of abiraterone acetate in Indian participants with metastatic, castration-resistant prostate cancer who have been prescribed abiraterone acetate as per locally approved prescribing information.

Conditions

Interventions

DRUG

Abiraterone Acetate

This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.

Sponsors & Collaborators

  • Johnson & Johnson Private Limited

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Private Limited Clinical Trial · Johnson & Johnson Private Limited

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608359 on ClinicalTrials.gov